A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial
暂无分享,去创建一个
G. Greenberg | S. Targan | P. Rutgeerts | S. Hanauer | B. Sands | W. Sandborn | B. Feagan | R. Panaccione | Subrata Ghosh | C. Guzzo | J. Johanns | C. Gasink | S. Lichtiger | M. Blank | S. Schreiber | Long-Long Gao | W. Villiers